HOME >> BIOLOGY >> NEWS
Romond heads up study and reduces breast cancer recurrence

LEXINGTON, Ky. (April 26, 2005) - Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.

Dr. Edward Romond, associate professor of medicine at the University of Kentucky College of Medicine and UK Markey Cancer Center, acts as principal investigator on the study and the National Surgical Adjuvant Breast and Bowel Project (NSABP) study chair.

"For women with this type of aggressive breast cancer, the addition of trastuzumab to chemotherapy appears to virtually reverse prognosis from unfavorable to good. We owe a huge debt of gratitude to the women whose participation in these trials has made it possible to show the substantial benefit of combining trastuzumab with chemotherapy for adjuvant treatment of women with HER-2 positive breast cancer," said Romond.

The clinical trials were sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by NSABP and the North Central Cancer Treatment Group (NCCTG), in collaboration with the Cancer and Leukemia Group B, the Eastern Cooperative Oncology Group, and the Southwest Oncology Group. Genentech Inc., which manufactures trastuzumab as Herceptin, provided the drug for the trials under the Cooperative Research and Development Agreement with NCI.

Information from over 3,300 patients enrolled in the studies was used for analysis. Patients with operable breast cancer, whose tumors over-expressed HER-2, were enrolled in these studies between February 2000 and April 2005. Patients are considered "HER-2 positive" if their cancer cells "overexpress," or make too much of, a protein called HER-2, which is found on the surface of cancer cells. T
'"/>

Contact: Louise DuPont
mldupo00@email.uky.edu
859-323-6363
University of Kentucky
26-Apr-2005


Page: 1 2

Related biology news :

1. The UAB heads a European research project on proteases and pathological processes
2. 2 heads are better than 1: 2 dysfunctional DNA repair pathways kill tumor cells
3. Counting heads or measuring space?
4. If you flaunt it, youve got it: How red-heads top the pecking order
5. Carnegie Mellon rover heads to Atacama Desert for final mission in 3-year search for life
6. University of Vermont heads translatlantic cardiovascular research network
7. New study warns limited carbon market puts 20 percent of tropical forest at risk
8. Clones on task serve greater good, evolutionary study shows
9. Pollution causes 40 percent of deaths worldwide, study finds
10. A study by the MUHC and McGill University opens a new door to understanding cancer
11. New study suggests Concord grape juice may provide protection against breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/11/2020)... Fla. (PRWEB) , ... March 11, 2020 , ... ... teleradiology and telemedicine company backed by Siemens Healthineers and several healthcare VC firms ... infected over 100,000 people in over 100 countries and has caused over 4,000 ...
(Date:3/5/2020)... SAN DIEGO (PRWEB) , ... ... ... Inc. today announces the formation of its Scientific Advisory Board (SAB) comprised ... prestigious academic institutions, immune-oncology centers, cell therapy centers, and private industry. Cytonus ...
(Date:3/4/2020)... ... March 04, 2020 , ... The Massachusetts Medical ... the MedTech IGNITE program’s 2020 IGNITE Cohort. The MedTech IGNITE Program is a ... nurture the next generation of medtech founders and entrepreneurs. IGNITE Cohort members get ...
Breaking Biology News(10 mins):
(Date:2/26/2020)... ... February 25, 2020 , ... Continuing its ... published the results of its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) ... human milk. These complex carbohydrates are indigestible and therefore function as a prebiotic ...
(Date:2/21/2020)... , ... February 21, 2020 , ... ... improve their manufacturing operations in order to adapt to new approaches like ‘Industry ... with the increasing demand for personalized medicine and therapies. But with an industry ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... results from a long-term follow-up clinical study of outpatient L4-L5 lumbar interspinous ... LLC). Unlike extension block design, the Inspan device fixates the spine to ...
(Date:2/3/2020)... ... February 03, 2020 , ... Ovation Travel ... Firm Travel, Technology Industry Travel and Biotech/Healthcare Industry Travel Indexes. , All of ... the following statistics:, Average airfare price paid Domestically, ...
Breaking Biology Technology:
Cached News: